

SUMMARY OF CHANGES

Ontario Drug Benefit Formulary/Comparative Drug Index

No. 39

Update: 13A Effective: Oct 23, 2006

DIN	PRODUCT	MFR	DBP
02242572	Actos 15mg Tab	LIL	2.1042
02242573	Actos 30mg Tab	LIL	2.9480
02242574	Actos 45mg Tab	LIL	4.4327

These products must be prescribed based on the following criteria for the treatment of type 2 diabetes in a patient with:

- Inadequate glycemic control (HbA1C>7%) using maximal doses of glyburide (10mg/day) AND metformin (2000mg/day); OR
- Inadequate glycemic control and demonstrated intolerance or contraindication to metformin and are on maximal doses of glyburide; OR
- Inadequate glycemic control and demonstrated intolerance or contraindication to glyburide and are on maximal doses of metformin; OR
- Demonstrated intolerance or contraindication to both glyburide AND metformin; OR
- Adequate glycemic control (HbA1c <=7%) who develops intolerance or contraindication to glyburide or metformin; OR
- HbA1c <=7% and greater than 50% of fasting blood glucose (FBG >7mmol/L) or post-prandial plasma glucose (PPG>10mmol/L) levels are not within target range and using maximally tolerated doses of glyburide and metformin.